EGFR and cancer: A study demonstrated that exosomes containing wild-type EGFR protein were internalized by EGFR mutant cancer cells through clathrin-dependent endocytosis, and then the downstream PI3K/Akt and MAPK signaling pathways were activated by the wild-type EGFR protein, thus triggering osimertinib resistance (77).